Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
ARCT compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name
ARCT
Arcturus Therapeutics Holdings Inc.
Change
Mkt cap
Revenue
Revenue
LLY
ELI Lilly & Co
Change
Mkt cap
Revenue
Revenue
vs
Compare
ARCT
Arcturus Therapeutics Holdings Inc.
vs
LLY
ELI Lilly & Co
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
ARCT: latest quarter is a loss; flow not drawable.
Method
›
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
ARCT, solid
LLY, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only ARCT
3
—
Biomedical Advanced Research and Development Authority (BARDA)
unlisted
customer
—
CSL Seqirus
unlisted
customer
—
Meiji Seika Pharma
unlisted
customer
Shared
0
No shared counterparties.
Only LLY
29
MCK
McKesson
customer
CAH
Cardinal Health
customer
VEEV
Veeva Systems
supplier
UTHR
United Therapeutics
customer
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
25 more · LLY chain
›
ARCT
Arcturus Therapeutics Holdings Inc.
Change
9.54
· pre 9.54
· delayed
Mkt cap
$271.2M
Revenue
$3M
Q2 FY26
Revenue
$82M
FY25
LLY
ELI Lilly & Co
Change
1,407.25
· pre 1,425.17
· delayed
Pre-market
Nov 4 '26
delayed
Mkt cap
$1.3T
Revenue
$24.4B
Q3 FY26
Revenue
$65.2B
FY25
vs
Compare
Pre-market
Nov 4 '26
delayed
ARCT
Arcturus Therapeutics Holdings Inc.
vs
LLY
ELI Lilly & Co
9.54
pre 9.54
delayed
Price
1,407.25
pre 1,425.17
delayed
$271.2M
Mkt cap
$1.3T
Q2 FY26
$3M
Revenue
$24.4B
Q3 FY26
FY25
$82M
Revenue
$65.2B
FY25
Change
Change
ARCT
9.54
vs
LLY
1,407.25
Pre-market
Nov 4 '26
delayed